All In Biotech

Drug Trial Radar · NCT02934529

Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

A Randomised Study to Assess the Efficacy of Cetuximab Rechallenge in Patients With Metastatic Colorectal Cancer (RAS Wild-type) Responding to First-line Treatment With FOLFIRI Plus Cetuximab

Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 673 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

673

Actual

Start

Mar 2015

Primary completion

Jan 30, 2025

Study completion Jan 30, 2025

Sponsor

Lead sponsor
Ludwig-Maximilians - University of MunichAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 17, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The FIRE-4 study aims to define a treatment concept for patients with RAS wild-type tumours, optimised with regard to overall survival. The first-line treatment will be conducted with FOLFIRI plus cetuximab, which resulted in a significantly prolonged overall survival versus bevacizumab in the FIRE-3 study. Following initial progression (PD1) it is recommended that the treatment be continued with FOLFOX plus bevacizumab, as this concept led to significantly prolonged survival in the E3200 study. Owing to the encouraging results of the Santini study , a cetuximab rechallenge in combination with irinotecan-based chemotherapy is to be performed as part of the third-line treatment in patients who showed a response defined according to RECIST 1.1 during the first-line treatment (tumour diameter \< -30%) or presented with stable tumour disease for at least 6 months (tumour diameter +20 to -30%). The concept of the ideal sequence has not yet been studied to date in a clinical trial.

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • IrinotecanDrug

    Irinotecan 180 mg/m² iv, 30 - 90 min., day 1, q d15

  • Folinic AcidDrug

    Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15

  • 5-FUDrug

    5-FU 400 mg/m² bolus day 1, q d15

  • 5-FUDrug

    5-FU 2400 mg/m² iv over 46 h day 1-2, q d15

  • CetuximabDrug

    cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) day 1 + 8

  • BevacizumabDrug

    Bevacizumab 7.5 mg/kg BW iv over 30 to 90 minutes: day 1

  • CapecitabineDrug

    Capecitabine 1250 mg/m2 2 x day p.o. day 1-14, q d15

  • regorafenibDrug

    160 mg per day (day 1-21) (repeated on day 28)

  • Irinotecan 125mgDrug

    Irinotecan 125 mg/m² iv, 60 - 90 min. weekly (D1, D8, D15, D22)

  • Cetuximab wklyDrug

    Cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) weekly (D1, D8, D15, D22, D29, D36)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: up to 55 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Klinikum der Universitaet Muenchen - Campus Grosshadern

    Munich, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.